Boron uptake in normal melanocytes and melanoma cells and boron biodistribution study in mice bearing B16F10 melanoma for boron neutron capture therapy

详细信息    查看全文

• 作者：Fernanda Fai?o-Flores (12) fernandafaiao@usp.br
  Paulo Rogério Pinto Coelho (3)
  Jo?o Dias Toledo Arruda-Neto (45)
  Maria Aparecida Pires Camillo (3)
  Silvya Stuchi Maria-Engler (6)
  Rose Eli Grassi Rici (7)
  Jorge Eduardo Souza Sarkis (3)
  Durvanei Augusto Maria (1) durvanei@usp.br
• 关键词：Boron neutron capture therapy – 10B measurement – Boronophenylalanine – B16F10 melanoma – C57Bl/6J mice
• 刊名：Radiation and Environmental Biophysics
• 出版年：2012
• 出版时间：August 2012
• 年：2012
• 卷：51
• 期：3
• 页码：319-329
• 全文大小：515.1 KB
• 参考文献：1. Barth RF (2003) A critical assessment of boron neutron capture therapy: an overview. J Neurooncol 62:1–5
  2. Barth RF, Matalka KZ, Bailey MQ, Staubus AE, Soloway AH, Moeschberger ML, Coderre JA, Rofstad EK (1994) A nude rat model for neutron capture therapy of human intracerebral melanoma. Int J Radiat Oncol Biol Phys 28:1079–1088
  3. Cho HJ, Chun KJ, Park KW, Chung YS, Kim HR (2007) Determination of boron in a black mouse by prompt gamma activation analysis. J Radioanal Nuclear Chem 272:404–407
  4. Coderre JA, Morris GM (1999) The radiation biology of boron neutron capture therapy. Radiat Res 151:1–18
  5. Coderre JA, Glass JD, Fairchild RG, Micca PL, Joel DD (1990) Selective delivery of boron by the melanin precursor analogue boronophenylalanine in tumors other than melanoma. Cancer Res 50:138–141
  6. Coderre JA, Slatkin DN, Micca PL, Ciallella JR (1991) Boron neutron capture therapy of a murine melanoma with p-boronophenylalanine: dose-response analysis using a morbidity index. Radiat Res 128:177–185
  7. Coderre JA, Button TM, Micca PL, Fisher CD, Nawrocky MM, Liu HB (1994) Neutron capture therapy of the 9L rat gliosarcoma using the p-boronophenylalanine-fructose complex. Int J Radiat Oncol Biol Phys 30:643–652
  8. Coelho PRP, Hernandes AC, Siqueira PTD (2002) Neutron flux calculation in a BNCT research facility implemented in IEA-R1 reactor. In: 10th International Congress on Neutron Capture Therapy. Research and development in neutron capture therapy. Wolfgang S, Raymond M, Andrea W. Essen, Germany (Bologna), pp 197–201
  9. Dagrosa MA, Viaggi M, Rebagliati RJ, Batistoni D, Kahl SB, Juvenal GJ, Pisarev MA (2005) Biodistribution of boron compounds in an animal model of human undifferentiated thyroid cancer for boron neutron capture therapy. Mol Pharm 2:151–156
  10. Fai?o-Flores F, Coelho PR, Arruda-Neto J, Maria DA (2011a) Boron neutron capture therapy induces cell cycle arrest and DNA fragmentation in murine melanoma cells. Appl Radiat Isot 69:1741–1744
  11. Fai?o-Flores F, Coelho PR, Muniz RO, Souza GS, Arruda-Neto J, Maria DA (2011b) Antitumor potential induction and free radicals production in melanoma cells by Boron Neutron Capture Therapy. Appl Radiat Isot 69:1748–1751
  12. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW Jr, Lowe SW, Soengas MS (2005) Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65:6294–6304
  13. Fidler IJ (1975) Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35:218–224
  14. Fukuda H, Hiratsuka J, Honda C, Kobayashi T, Yoshino K, Karashima H, Takahashi J, Abe Y, Kanda K, Ichihashi M et al (1994) Boron neutron capture therapy of malignant melanoma using 10B-paraboronophenylalanine with special reference to evaluation of radiation dose and damage to the normal skin. Radiat Res 138:435–442
  15. Gautier EA, Roberti MJ, Gettar RT, Jiménez Rebagliati R, Batistoni DA (2007) Assessment of chemical purity of 10B-enriched p-boronophenylalanine by high-performance liquid chromatography coupled on-line with inductively coupled plasma optical emission spectrometry. Anal Bioanal Chem 388:499–503
  16. Gogas HJ, Kirkwood JM, Sondak VK (2009) Chemotherapy for metastatic melanoma: time for a change? Cancer 109:455–464
  17. Ichikawa H, Taniguchi E, Fujimoto T, Fukumori Y (2009) Biodistribution of BPA and BSH after single, repeated and simultaneous administrations for neutron-capture therapy of cancer. Appl Radiat Isot 67:S111–S114
  18. Ikeuchi I, Amano T (1978) A colorimetric determination of boron in biological materials. Chem Pharm Bull (Tokyo) 26:2619–2623
  19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249
  20. Jiang G, Liu YQ, Wei ZP, Pei DS, Mao LJ, Zheng JN (2010) Enhanced anti-tumor activity by the combination of a conditionally replicating adenovirus mediated interleukin-24 and dacarbazine against melanoma cells via induction of apoptosis. Cancer Lett 294:220–228
  21. Kamida A, Fujita Y, Kato I, Iwai S, Ono K, Suzuki M, Sakurai Y, Yura Y (2008) Effect of neutron capture therapy on the cell cycle of human squamous cell carcinoma cells. Int J Radiat Biol 84:191–199
  22. Kreimann EL, Miura M, Itoiz ME, Heber E, Garavaglia RN, Batistoni D, Rebagliati RJ, Roberti MJ, Micca PL, Coderre JA, Schwint AE (2003) Biodistribution of a carborane-containing porphyrin as a targeting agent for boron neutron capture therapy of oral cancer in the hamster cheek pouch. Arch Oral Biol 48:223–232
  23. Larrosa M, Tomás-Barberán FA, Espín JC (2003) Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells. J Agric Food Chem 51:4576–4584
  24. Mattiello EM, Ruiz HA, Silva IR, Sarkis JES (2011) Use of the HRICP-MS technique for the evaluation of boron isotopes in eucalitpus plants. Quím Nova 34:512–515
  25. Mendes PF, Xander P, Novaes e Brito RR, Mortara RA, Jasiulionis MG, Lopes JD (2008) A cell surface 230 kDa protein from murine melanoma involved with tumor malignancy. Cancer Lett 262:276–285
  26. Menéndez PR, Roth BM, Pereira MD, Casal MR, González SJ, Feld DB, Santa Cruz GA, Kessler J, Longhino J, Blaumann H, Jiménez Rebagliati R, Calzetta Larrieu OA, Fernández C, Nievas SI, Liberman SJ (2009) BNCT for skin melanoma in extremities: updated Argentine clinical results. Appl Radiat Isot 67:S50–S53
  27. Meyskens FL Jr (1981) Modulation of abnormal growth by retinoids: a clinical perspective of the biological phenomenon. Life Sci 28:2323–2327
  28. Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H (1989) Treatment of malignant melanoma by single thermal-neutron capture therapy with melanoma seeking B-10 compound. Lancet 2:388–389
  29. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
  30. Probst TU (1999) Methods for boron analysis in boron neutron capture therapy (BNCT). A review. Fresenius J Anal Chem 364:391–403
  31. Sauerwein W (1993) Principles and history of neutron capture therapy. Strahlenther Onkol 169:1–6
  32. Soloway AH, Tjarks W, Barnum A, Rong FG, Barth RF, Codogni IM, Wilson JG (1998) The chemistry of neutron capture therapy. Chem Rev 98:1515–1562
  33. Suzuki M, Nagata K, Masunaga S, Kinashi Y, Sakurai Y, Maruhashi A, Ono K (2004) Biodistribution of 10B in a rat liver tumor model following intra-arterial administration of sodium borocaptate (BSH)/degradable starch microspheres (DSM) emulsion. Appl Radiat Isot 61:933–937
  34. Trivillin VA, Heber EM, Rao M, Cantarelli MA, Itoiz ME, Nigg DW, Calzetta O, Blaumann H, Longhino J, Schwint AE (2008) Boron neutron capture therapy (BNCT) for the treatment of spontaneous nasal planum squamous cell carcinoma in felines. Radiat Environ Biophys 47:147–155
  35. Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H (2002) Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 61:729–737
  36. Wittig A, Michel J, Moss RL, Stecher-Rasmussen F, Arlinghaus HF, Bendel P, Mauri PL, Altieri S, Hilger R, Salvadori PA, Menichetti L, Zamenhof R, Sauerwein WA (2008a) Boron analysis and boron imaging in biological materials for Boron Neutron Capture Therapy (BNCT). Crit Rev Oncol Hematol 68(1):66–90
  37. Wittig A, Malago M, Collette L, Huiskamp R, Buhrmann S, Nievaart V, Kaiser GM, Jockel KH, Schmid KW, Ortmann U, Sauerwein WA (2008b) Uptake of two 10B-compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001). Int J Cancer 122:1164–1171
  38. Wittig A, Huiskamp R, Moss RL, Bet P, Kriegeskotte C, Scherag A, Hilken G, Sauerwein WA (2009) Biodistribution of (10)B for Boron Neutron Capture Therapy (BNCT) in a mouse model after injection of sodium mercaptoundecahydro-closo-dodecaborate and l-para-boronophenylalanine. Radiat Res 172:493–499
  39. Yamamoto T, Nakai K, Matsumura A (2008) Boron neutron capture therapy for glioblastoma. Cancer Lett 262:143–152
  40. Zhao W, Entschladen F, Liu H, Niggemann B, Fang Q, Zaenker KS, Han R (2003) Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and fibrosarcoma cells. Cancer Detect Prev 27:67–75
• 作者单位：1. Laboratory of Biochemistry and Biophysics, Butantan Institute, 1500 Vital Brasil Avenue, S?o Paulo, SP 05503-900, Brazil2. Faculty of Medicine, University of S?o Paulo, S?o Paulo, SP, Brazil3. Institute for Nuclear and Energy Research, S?o Paulo, SP, Brazil4. Physics Institute, University of S?o Paulo, S?o Paulo, SP, Brazil5. CEPESq/Uniítalo—Italy-Brazilian University Center, S?o Paulo, SP, Brazil6. Department of Clinical Chemistry and Toxicology, School of Pharmaceutical Sciences, University of S?o Paulo, S?o Paulo, SP, Brazil7. Faculty of the Veterinary Medicine and Zootechny, Department of Surgery, University of S?o Paulo, S?o Paulo, SP, Brazil
• ISSN：1432-2099

文摘

Information on 10B distribution in normal tissues is crucial to any further development of boron neutron capture therapy (BNCT). The goal of this study was to investigate the in vitro and in vivo boron biodistribution in B16F10 murine melanoma and normal tissues as a model for human melanoma treatment by a simple and rapid colorimetric method, which was validated by HR-ICP-MS. The B16F10 melanoma cell line showed higher melanin content than human melanocytes, demonstrating a greater potential for boronophenylalanine uptake. The melanocytes showed a moderate viability decrease in the first few minutes after BNCT application, stabilizing after 75 min, whereas the B16F10 melanoma showed the greatest intracellular boron concentration at 150 min after application, indicating a different boron uptake of melanoma cells compared to normal melanocytes. Moreover, at this time, the increase in boron uptake in melanoma cells was approximately 1.6 times higher than that in normal melanocytes. The 10B concentration in the blood of mice bearing B16F10 melanoma increased until 90 min after BNCT application and then decreased after 120 min, and remained low until the 240th minute. On the other hand, the 10B concentration in tumors was increased from 90 min and maximal at 150 min after application, thus confirming the in vitro results. Therefore, the present in vitro and in vivo study of 10B uptake in normal and tumor cells revealed important data that could enable BNCT to be possibly used as a treatment for melanoma, a chemoresistant cancer associated with high mortality.